Ipca Laboratories Ltd has made an open offer to the shareholders of Hyderabad-based Krebs Biochemicals and Industries Ltd (KBIL). Mumbai-based formulates and API maker Ipca will acquire about 35.73 lakh shares of Krebs (of the face value of Rs. 10 each) at a price of Rs. 54 per share.
Established in 1991, KBIL undertakes contract manufacturing. It has expertise and infrastructure in the areas of chemical synthesis, fermentation and enzymatic technologies.